Paula McDermott
Critical Care Medicine · Littleton, CONPI 1891931986
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Pfizer at 46.7% of the total. 2025 is the largest year on record at $24,378, 6.2 times the $3,961 reported in 2021. Among critical care medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $124.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$16K
- Alnylam Pharmaceuticals Inc.$7K
- Akcea Therapeutics, Inc.$3K
- Abbott$1K
- AstraZeneca$1K
- Cvrx, Inc.$984
- plus $5K from 21 others
What the payments were for
- Consulting fees$9,10027%
- Speaking & faculty fees$12,65338%
- Travel & lodging$2,1526%
- Food & beverage$9,67029%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 55 | $15,700 |
| Alnylam Pharmaceuticals Inc. | 23 | $7,430 |
| Akcea Therapeutics, Inc. | 5 | $2,730 |
| Abbott | 17 | $1,083 |
| AstraZeneca | 23 | $1,009 |
| Cvrx, Inc. | 9 | $984 |
| Impulse Dynamics (USA) Inc. | 12 | $936 |
| E.r. Squibb & Sons, L.L.C. | 38 | $741 |
| Boston Scientific | 9 | $712 |
| Novartis | 10 | $480 |
| Bridgebio Pharma, Inc. | 10 | $336 |
| Amgen | 18 | $307 |
| Boehringer Ingelheim | 7 | $211 |
| ZOLL Respicardia, Inc. | 1 | $143 |
| Merck | 5 | $136 |
| Scpharmaceuticals Inc. | 2 | $116 |
| Bayer | 6 | $111 |
| Novo Nordisk | 1 | $98 |
| Abiomed | 1 | $96 |
| Lexicon Pharmaceuticals, Inc. | 5 | $82 |
| AbbVie | 4 | $57 |
| Johnson & Johnson | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| Vifor Pharma, Inc. | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Atricure, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$14,209
- AMVUTTRA$6,972
- TEGSEDI$1,800
- VYNDAMAX$992
- OPTIMIZER$925
- Barostim Neo System$824
- CARDIOMEMS$562
- WAINUA$385
- FARXIGA$369
- WATCHMAN Access System$249
- Watchman$239
- ENTRESTO$230
- GENERAL TACHY$147
- remede System$143
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$138
- Attruby$127
- JARDIANCE$119
- FUROSCIX$101
How this compares
$33,618 in reported general payments places this provider in the 95th percentile of 141 critical care medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 175 | $4,181,736 |
| VyndaqelTafamidis Meglumine | 27 | $738,001 |
| JardianceEmpagliflozin | 376 | $310,531 |
| EntrestoSacubitril/Valsartan | 127 | $129,367 |
| FarxigaDapagliflozin Propanediol | 69 | $66,468 |
| EliquisApixaban | 62 | $61,403 |
| XareltoRivaroxaban | 18 | $19,046 |
| Metoprolol Succinate | 361 | $4,354 |
| Eplerenone | 59 | $4,132 |
| Valsartan | 216 | $3,868 |
| Torsemide | 153 | $3,447 |
| Spironolactone | 482 | $2,608 |
| Bumetanide | 43 | $1,887 |
| Potassium Chloride | 86 | $1,300 |
| Furosemide | 178 | $805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $15,700 | $4,981,140264 claims |
| Boehringer IngelheimJardiance | $211 | $310,531376 claims |
| NovartisEntresto | $480 | $129,367127 claims |
| AstraZenecaFarxiga | $1,009 | $66,46869 claims |
| Johnson & JohnsonXarelto | $30 | $19,04618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 141 critical care medicine providers in Colorado.
Other critical care medicine in Littleton
- Nitin GuptaLittleton$35K
- Erin RiggleLittleton$25K
- Kelly GreeneLittleton$18K
- Alecia BryndaLittleton$3K
- Peter HountrasAurora$86K
- Paul WischmeyerAurora$78K
- Chakradhar KotaruGreenwood Village$61K
- Gregory CosgroveDenver$46K
- Walter ConwellDenver$42K
- David HsiaDenver$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.